Saks, Nordstrom, Ma...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$17.21 0.59 | 3.55%
05/21/13 - 02:10 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| ARIA | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -16.65 | 1.96 | 304.61 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | -97.80 | -0.93 | -0.59 |
| Net Income | 1.76 | 0.00 | |
| EPS | 0.56 | 0.00 |
Earnings for ARIA:
| EBITDA | -205.00 |
| REVENUE | 558.00K |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.41 | $-0.44 | $-1.64 | $-1.31 |
| Number of Analysts | 10 | 9 | 12 | 11 |
| High Estimate | $-0.38 | $-0.38 | $-1.25 | $-0.86 |
| Low Estimate | $-0.45 | $-0.47 | $-1.73 | $-1.71 |
| Prior Year | $-0.31 | $-0.32 | $-1.34 | $-1.64 |
| Growth Rate (Year over Year) | -30.65% | -36.81% | -22.76% | 20.59% |
Portfolios with ARIA
- Portfolio NameUser Type
- ProSteven Cohen - SAC Capital
- ProDaniel Loeb - Third Point
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
Latest ARIA Headlines from TheStreet
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine 04.04.13 | 10:04 am
- Ariad Stock Falls On Unusually High Volume (ARIA) 04.03.13 | 02:04 pm
- The Survey Says: Ariad's Leukemia Drug Is Toxic 04.03.13 | 01:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day 03.28.13 | 05:03 pm
- Ariad Pharma Falls On Weak Leukemia Drug Prescriptions 03.27.13 | 12:03 pm
- Ariad Stock Falls On Unusually High Volume (ARIA) 03.25.13 | 04:03 pm
- Cramer's Top Stock Picks: ARIA ALKS LINE KORS WFM 02.28.13 | 06:02 am
- Cramer's 'Mad Money' Recap: I Told You So 02.27.13 | 08:02 pm
Press Releases for ARIA
- ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union - Business Wire 03.22.13 | 08:03 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.20.13 | 07:03 am
- ARIAD To Present At Barclays Global Healthcare Conference - Business Wire 03.06.13 | 07:03 am
- ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.28.13 | 07:02 am
- ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013 - Business Wire 02.25.13 | 07:02 am
- Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire) - Business Wire 02.21.13 | 02:02 am
- ARIAD To Present At The RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 07:02 am
- ARIAD To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.08.13 | 07:02 am
- ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results - Business Wire 02.05.13 | 07:02 am
- ARIAD Announces Completion Of Public Offering - Business Wire 01.29.13 | 04:01 pm
Partner Headlines for ARIA
- Pre-Market Earnings Report for February 25, 2013 : LOW, FE, HTZ, DCI, KOS, ARIA, DDD, BGC, CTB, CWH, HL, DNDN - NASDAQ 02.22.13 | 09:02 pm
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, $32 PT - Benzinga 12.07.12 | 09:12 am
- Data Published on ARIAD Candidate - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- ARIAD Seeks Ponatinib Approval - Analyst Blog - Zacks 10.02.12 | 06:10 pm
- ARIAD Partner Withdraws PMA - Analyst Blog - NASDAQ 09.19.12 | 08:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - NASDAQ 08.31.12 | 10:08 pm
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - Zacks 08.31.12 | 06:08 pm
